IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination

Journal of Neuroimmunology

Volumn 233, Issue 1-2, 2011, Pages 147-159

  Ren, Zhihua ^a   Wang, Yan ^a   Liebenson, David ^a   Liggett, Thomas ^a   Goswami, Rajendra ^a   Stefoski, Dusan ^a   Balabanov, Roumen ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Caspase 1; CNS inflammation; Experimental autoimmune encephalomyelitis; Glial cells; Interferon regulatory factor 1; Multiple sclerosis

Indexed keywords

INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA CONVERTING ENZYME;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; FEMALE; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; WHITE MATTER;

ANIMALS; CELLS, CULTURED; DEMYELINATING AUTOIMMUNE DISEASES, CNS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOMODULATION; INTERFERON REGULATORY FACTOR-1; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROGLIA; SIGNAL TRANSDUCTION;

EID: 79953304868     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.01.001     Document Type: Article

References (49)

1. Agresti C., Bernardo A., Del Russo N., Marziali G., Battistini A., Aloisi F., Levi G., Coccia E. Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes. Eur. J. Neurosci. 1998, 10:2975-2983.
2. Alexander W., Starr R., Fenner J., Scott C., Handman E., Spring N., Corbin J., Cornish A., Darwishe R., Owczarek C., Kay T., Nicola N., Hertzog P., Metcalf D., Hilton D. Socs1 is a critical inhibitor of interferon-gamma signaling and prevents the potentially fatal action of this cytokine. Cell 1999, 98:598-608.
3. Balabanov R., Strand K., Goswami R., McMahon E., Begolka W., Miller S., Popko B. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 2007, 27:2013-2024.
4. Barnett M., Prineas J. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004, 55:458-468.
5. Bergsbaken T., Fink L., Cookson T. Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 2009, 7:99-109.
6. Bø L., Vedeler C.A., Nyland H.I., Trapp B.D., Mørk S.J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 2003, 62:723-732.
7. Buch T., Uthoff-Hachenberg C., Waisman A. Protection from autoimmune brain inflammation in mice lacking IFN-regulatory factor-1 is associated with Th2-type cytokines. Int. Immunol. 2003, 15:855-866.
8. Burt R.K., Loh Y., Cohen B., Stefoski D., Balabanov R., Katsamakis G., Oyama Y., Russell E.J., Stern J., Muraro P., Rose J., Testori A., Bucha J., Jovanovic B., Milanetti F., Storek J., Voltarelli J.C., Burns W.H. Autologous non-myeloablative hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009, 8:244-253.
9. Butzkueven H., Zhang J., Hanninen M., Hochrein H., Chionh F., Shipham K., Emery B., Turnley A., Petratos S., Ernst M., Bartlett P., Kilpatrick T. LIF receptor signaling limits immune mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. 2002, 8:613-619.
10. Cassiani-Ingoni R., Muraro P.A., Magnus T., Reichert-Scrivner S., Schmidt J., Huh J., Quandt J.A., Bratincsak A., Shahar T., Eusebi F., Sherman L.S., Mattson M.P., Martin R., Rao M.S. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J. Neuropathol. Exp. Neurol. 2007, 66:637-649.
11. Charo I., Ransohoff R. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354:610-621.
12. Feng X., Petraglia A.L., Chen M., Byskosh P.V., Boos M.D., Reder A.T. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J. Neuroimmunol. 2002, 129:205-215.
13. Fortunato G., Calcagno G., Bresciamorra V., Salvatore E., Filla A., Capone S., Liquori R., Borelli S., Gentile L., Borelli F., Borgia G., Sachetti L. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J. Interferon Cytokine Res. 2008, 28:141-152.
14. Furlan R., Martino G., Galbiati F., Poliani P.L., Smiroldo S., Bergami A., Desina G., Comi G., Flavell R., Su M.S., Adorini L. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 1999, 163:2403-2409.
15. Heine S., Ebnet J., Maysami S., Stangel M. Effects of interferon-beta on oligodendroglial cells. J. Neuroimmunol. 2006, 177:173-180.
16. Hickey W., Kimura H. Perivascular microglial cells of the CNS are bone-marrow derived and present antigen in vivo. Science 1988, 239:290-293.
17. Hisahara S., Hideyuki O., Masayuki M. Caspase-mediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination. Neurosci. Res. 2003, 46:387-397.
18. Höftberger R., Aboul-Enein F., Brueck W., Lucchinetti C., Rodriguez M., Schmidbauer M., Jellinger K., Lassmann H. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004, 14:43-50.
19. Hovelmeyer N., Hao Z., Kranidioti K., Kassiotis G., Buch T., Frommer F., von Hoch L., Kramer D., Minichiello L., Kollias G., Lassmann H., Waisman A. Apoptosis of oligodendrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J. Immunol. 2005, 175:5875-5884.
20. Huseby E., Liggit D., Brabb T., Schnamel B., Ohlen C., Goverman J. A pathogenic role for myelin-specific CD8 (+) T cells in a model for multiple sclerosis. J. Exp. Med. 2001, 194:669-676.
21. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 1996, 26:1641-1646.
22. Lassmann H. Multiple sclerosis pathology: evaluation of pathogenic concepts. Brain Pathol. 2005, 15:217-222.
23. Lee J., Hur J., Lee P., Kim J.Y., Cho N., Kim S.Y., Kim H., Lee M.S., Suk K. Dual role of inflammatory stimuli in activation-induced cell death of mouse microglial cells. Initiation of two separate apoptotic pathways via induction of interferon regulatory factor-1 and caspase-11. J. Biol. Chem. 2001, 276:32956-32965.
24. Liggett T., Melnikov A., Tilwalli S., Yi Q., Chen H., Replogle C., Feng X., Reder A., Stefoski D., Balabanov R., Levenson V. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 2010, 290:16-21.
25. Lin R., Hiscott J. A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol. Cell. Biochem. 1999, 191:169-180.
26. Lin W., Kemper A., Dupree J., Harding H., Ron D., Popko B. Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 2006, 129:1306-1318.
27. Lin W., Bailey S.L., Ho H., Harding H.P., Ron D., Miller S.D., Popko B. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J. Clin. Invest. 2007, 117:448-456.
28. Linker R., Maüer M., Gaupp S., Martini R., Holtmann L., Giess R., Rieckmann P., Lassmann H., Toyka K., Sendtner M., Gold R. CNTF is a major protective factor in demyelinating CNS disease: a neuroprotective cytokine as modulator in neuroinflammation. Nat. Med. 2002, 8:620-624.
29. Lohoff M., Mak T. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat. Rev. Immunol. 2005, 5:125-135.
30. Lucchinetti C., Brück W., Parisi J., Scheitauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
31. Mariathasan S., Newton K., Monack D., Vucic D., French D., Lee W., Roose-Girma M., Erickson S., Dixit V. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004, 430:213-218.
32. McMahon E., Bailey S., Castenada C., Waldner H., Miller S. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 2005, 11:335-339.
33. Ming X., Li W., Maeda Y., Cook S., Chapin J., Husar W., Dowling P. Caspase 1 expression in multiple sclerosis plaques and cultured glial cells. J. Neurol. Sci. 2002, 197:9-18.
34. Mir M., Tolosa L., Asensio V.J., Lladó J., Olmos G. Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation. J. Neuroimmunol. 2008, 204:101-109.
35. Noteworthy J., Lucchinetti C., Rodriguez M., Weinshenker B. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
36. Panitch N., Hirsch R., Haley A., Johnson K. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
37. Ramana C., Gil M., Schreiber R., Stark G. STAT1-dependent and independent pathways in IFN-γ-dependent signaling. Trends Immunol. 2002, 23:96-101.
38. Ren Z., Wang Y., Tao D., Liebenson D., Liggett T., Goswami R., Stefoski D., Balabanov R. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis. J. Neuroimmune Pharmacol. 2010, 5:260-265.
39. Satoh J., Kuroda Y. Differing effects of IFN beta vs IFN gamma in MS: gene expression in cultured astrocytes. Neurology 2001, 57:681-685.
40. Starr R., Wilson T., Viney E., Murray L., Rayner J., Jenkins J., Brendan J., Gonda T., Alexander W., Metcalf D., Nicola N., Hilton J. A family of cytokine inducible inhibitors of signaling. Nature 1997, 387:917-921.
41. Steinman L., Zamvil S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
42. Tada Y., Ho A., Matsuyma T., Mak T. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J. Exp. Med. 1998, 185:231-238.
43. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. Family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 2001, 19:623-635.
44. Trapp B.D., Peterson J., Ransohoff R., Rudick R., Mørk S., Bø L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
45. Trebst C., Heine S., Lienenklaus S., Lindner M., Baumgärtner W., Weiss S., Stangel M. Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination. Acta Neuropathol. 2007, 114:587-596.
46. Vartanian T., Li Y., Zhao M., Stefansson K. Interferon-γ induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1995, 7:732-743.
47. Wang Y., Ren Z., Tao D., Tilwalli S., Goswami R., Balabanov R. STAT1/IRF-1 signaling pathway mediates the injurious effect of interferon-gamma on oligodendrocyte progenitor cells. Glia 2010, 58:195-209.
48. Wannamaker W., Davies R., Namchuk M., Pollard J., Ford P., Ku G., Decker C., Charifson P., Weber P., Germann U.A., Kuida K., Randle J.C. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid (2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J. Pharmacol. Exp. Ther. 2007, 321:509-516.
49. Williams A., Piaton G., Lubetzki C. Astrocytes-friends or foes in multiple sclerosis?. Glia 2007, 55:1300-1312.